DM-199 is under clinical development by DiaMedica Therapeutics and currently in Phase II for Diabetic Nephropathy. According to GlobalData, Phase II drugs for Diabetic Nephropathy have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DM-199’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DM-199 is under development for the treatment of diabetic nephropathy (diabetic kidney disease), other metabolic diseases, acute ischemic stroke, chronic kidney diseases in patients with type-1 diabetes and vascular dementia, IgA nephropathy. The drug candidate is administered through subcutaneous and intravenous route. DM-199 is a recombinant human tissue kallikrein-1 protein known as rhKLK-1.
The drug candidate was also under development for Alzheimer's disease, rheumatoid arthritis, type 2 diabetes, type 1 diabetes, acute kidney injury and Alport syndrome.
DiaMedica Therapeutics overview
DiaMedica Therapeutics (DiaMedica), formerly DiaMedica, is a biopharmaceutical company. It develops innovative medicines for the treatment neurological and kidney diseases. Its lead product candidate DM-199, is a human recombinant protein that treats diabetes type 1 and type 2, and associated complications including diabetic kidney disease and alport syndrome; and DM300 for treating acute pancreatitis. DiaMedica’s DM199 is also used for the treatment of diabetic nephropathy and post-insult treatment from acute ischemic stroke (AIS). The company discovers and develops novel therapies for kidney dysfunction and metabolic disorders. The company also provides clinical trial services. DiaMedica is headquartered in Minneapolis, Minnesota, the US.
For a complete picture of DM-199’s drug-specific PTSR and LoA scores, buy the report here.